Synaptogenix Net Working Capital from 2010 to 2025

SNPX Stock  USD 2.84  0.06  2.07%   
Synaptogenix Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital will likely drop to about 26.3 M in 2025. During the period from 2010 to 2025, Synaptogenix Net Working Capital regression line of annual values had r-squared of  0.31 and arithmetic mean of  20,788,864. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
30.2 M
Current Value
26.3 M
Quarterly Volatility
7.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Synaptogenix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synaptogenix's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 1.8 M or Interest Income of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.19 or PTB Ratio of 0.14. Synaptogenix financial statements analysis is a perfect complement when working with Synaptogenix Valuation or Volatility modules.
  
Check out the analysis of Synaptogenix Correlation against competitors.
For more information on how to buy Synaptogenix Stock please use our How to Invest in Synaptogenix guide.

Latest Synaptogenix's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Synaptogenix over the last few years. It is Synaptogenix's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Synaptogenix's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
5.1M33.5M37.3M26.3M30.2M26.3M555%11%-30%15%-13%100%
       Timeline  

Synaptogenix Net Working Capital Regression Statistics

Arithmetic Mean20,788,864
Geometric Mean19,190,622
Coefficient Of Variation38.14
Mean Deviation6,198,783
Median17,397,094
Standard Deviation7,928,653
Sample Variance62.9T
Range32.2M
R-Value0.55
Mean Square Error46.7T
R-Squared0.31
Significance0.03
Slope923,012
Total Sum of Squares943T

Synaptogenix Net Working Capital History

202526.3 M
202430.2 M
202326.3 M
202237.3 M
202133.5 M
20205.1 M

About Synaptogenix Financial Statements

Synaptogenix investors use historical fundamental indicators, such as Synaptogenix's Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Synaptogenix. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital30.2 M26.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Synaptogenix Stock Analysis

When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.

Trending Assets

RVPH
Reviva Pharmaceuticals
1.56  -0.07  -4.29 
ANVS
Annovis Bio
2.13  -0.1  -4.48 
CYTH
Cyclo Therapeutics
0.89  -0.06  -6.32 
INMB
INmune Bio
8.59  -0.9  -9.48 
News Freq…Investor S…